Cameron’s Law

Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.

Client expense: $53,142 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to COVID vaccine access and reimbursement; Issues related to the Orphan Drug Tax Credit; issues related to the deduction of research and development expenditures; H.R. 1350, Camerons Law; S.866/H.R.2673, American Innovation and R&D Competitiveness Act of 2023.

Client expense: $650,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to Section 174 R&D Amortization, including H.R. 2673 - American Innovation and R&D Competitiveness Act of 2023 and S. 866 - American Innovation and Jobs Act and H.R. 7024 - The Tax Relief for American Families and Workers Act of 2024 Issues related to the Orphan Drug Tax Credit, including H.R. 1350 - Camerons Law

Client expense: $90,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.

H.R. 1350, Camerons Law S.866/H.R.2673, American Innovation and R&D Competitiveness Act of 2023. Issues related to the Orphan Drug Tax Credit; issues related to the deduction of research and development expenditures

Client expense: $950,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.

Client expense: $140,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174).

H.R. 1350, Camerons Law H.R. 5376 - Share the Savings with Seniors Act S.866/H.R.2673, American Innovation and R&D Competitiveness Act of 2023. Issues related to the Orphan Drug Tax Credit; issues related to the deduction of research and development expenditures

Client expense: $700,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.

Client expense: $170,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).

Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350 - Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R.1805 - Leos Law. Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R.830/S.1375 - HELP Copays Act. H.R.5539 - ORPHAN Cures Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350 - Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R.1805 - Leos Law. Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R.830/S.1375 - HELP Copays Act. H.R.5539 - ORPHAN Cures Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the Orphan Drug Tax Credit Issues related to the deduction of research and development expenditures H.R. 1350, Camerons Law H.R. 2673, American Innovation and R&D Competitiveness Act of 2023

Client expense: $830,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.

Client expense: $105,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).

Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, Leos Law.

Client expense: Not reported · Firm income: $20,000

-Issues related to the Orphan Drug Tax Credit. -Issues related to the deduction of research and development expenditures. -H.R. 1350, Camerons Law. -H.R.2673, American Innovation and R&D Competitiveness Act of 2023.

Client expense: $950,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4170 - LIFT the BAR Act H.R. 5008 - Health Equity and Access under the Law for Immigrant Families Act of 2023 H.R.1805 - Leo's Law H.R.1350 - Cameron's Law

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R.1805, Leos Law. Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R.830, S.1375, The HELP Copays Act. H.R.5539, The ORPHAN Cures Act.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350 - Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R.1805 - Leos Law. Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R.830/S.1375 - HELP Copays Act. H.R.5539 - ORPHAN Cures Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.

Client expense: $250,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.

Client expense: $250,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.

Client expense: $175,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246).

H.R.2811: Limit, Save, Grow Act of 2023 Biofuels (Non-Funding) ---Incentives for Sustainable Aviation Fuels ---Sustainable Aviation Fuels Tax Credit Capital Formation Incentives ---H.R.368: American Innovation Act of 2023 ---H.R.2624: Helping Startups Continue to Grow Act ---H.R.2673: American Innovation and R&D Competitiveness Act ---H.R.2792: Small Entity Update Act ---S.866: American Innovation and Jobs Act ---A bill to amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities (Discussion Draft) ---A bill to amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research. (Discussion Draft) ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Innovation and Growth Now by Investing in Tomorrow's Enterprises (IGNITE) American Innovation Act (Discussion Draft) ---JOBS Act 4.0 ---Net Operating Loss Advance Refunds Orphan Drug Issues ---H.R.1350: Cameron's Law Renewable Chemicals/Bio-based Products (Non-Funding) ---Investment Tax Credit ---Production Tax Credit Research & Development Tax Credit Reforms ---H.R.2673: American Innovation and R&D Competitiveness Act ---S.866: American Innovation and Jobs Act ---A bill to amend the Internal Revenue Code of 1986 to provide for credits against tax for domestic medical and drug manufacturing and advanced medical manufacturing equipment. (Discussion Draft) ---Expensing of R&D Expenditures ---House - Section 174 Amortization ---R&D Payroll Credit Vaccine Injury Compensation Program ---FY 2024 Appropriations ---Countermeasure Injury Compensation Fund Amendment Act (Discussion Draft) ---Vaccine Injury Compensation Modernization Act (Discussion Draft) ---Vaccine Access Improvement Act (Discussion Draft) ---VICP CICP (Discussion Draft)

Issues related to the Orphan Drug Tax Credit. Issues related to the deduction of research and development expenditures. H.R. 1350, Camerons Law. H.R.2673, American Innovation and R&D Competitiveness Act of 2023.

Client expense: $830,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R.1805, Leos Law. Reauthorization of the Pandemic and All-Hazards Preparedness Act. Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R.830, S.1375, The HELP Copays Act.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.2811: Limit, Save, Grow Act of 2023 Biofuels (Non-Funding) ---Incentives for Sustainable Aviation Fuels ---Sustainable Aviation Fuels Tax Credit Capital Formation Incentives ---H.R.368: American Innovation Act of 2023 ---H.R.2624: Helping Startups Continue to Grow Act ---H.R.2673: American Innovation and R&D Competitiveness Act ---H.R.2792: Small Entity Update Act ---S.866: American Innovation and Jobs Act ---A bill to amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities (Discussion Draft) ---A bill to amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research. (Discussion Draft) ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Innovation and Growth Now by Investing in Tomorrow's Enterprises (IGNITE) American Innovation Act (Discussion Draft) ---JOBS Act 4.0 ---Net Operating Loss Advance Refunds Orphan Drug Issues ---H.R.1350: Cameron's Law Renewable Chemicals/Bio-based Products (Non-Funding) ---Investment Tax Credit ---Production Tax Credit Research & Development Tax Credit Reforms ---H.R.2673: American Innovation and R&D Competitiveness Act ---S.866: American Innovation and Jobs Act ---A bill to amend the Internal Revenue Code of 1986 to provide for credits against tax for domestic medical and drug manufacturing and advanced medical manufacturing equipment. (Discussion Draft) ---Expensing of R&D Expenditures ---House - Section 174 Amortization ---R&D Payroll Credit Vaccine Injury Compensation Program ---FY 2024 Appropriations ---Countermeasure Injury Compensation Fund Amendment Act (Discussion Draft) ---Vaccine Injury Compensation Modernization Act (Discussion Draft) ---Vaccine Access Improvement Act (Discussion Draft) ---VICP CICP (Discussion Draft)

Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, Leos Law.

Client expense: Not reported · Firm income: $20,000

Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350 - Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R.1805 - Leos Law. Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R.830, S.1375 - The HELP Copays Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.

Client expense: $160,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Senate HELP Minority- FDA Modernization H.R. 2471 - Consolidated Appropriations Act, 2022 (117th) H.R. 1350 - Camerons Law S. 1906 - Promising Pathway Act

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

Senate HELP Minority- FDA Modernization H.R. 2471 - Consolidated Appropriations Act, 2022 (117th) H.R. 1350 - Camerons Law S. 1906 - Promising Pathway Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

H.R. 485 - Protecting Health Care for All Patients Act of 2023 H.R.1350 - Camerons Law H.R.1805 - Leos Law S.866 - American Innovation and Jobs Act H.R.2673 - American Innovation and R&D Competitiveness Act of 2023 H.R.5376 - Inflation Reduction Act of 2022 (117th) H.R.2471 - Consolidated Appropriations Act, 2022 (117th)

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, Leos Law.

Client expense: $250,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA comments with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Opposing the SMART Act (S. 1246).

Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; Medicare Part D redesign; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, The Rare Disease Clinical Trials Pandemic Disruption Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act. H.R. 2673, The American Innovation and R&D Competitiveness Act.

Client expense: Not reported · Firm income: $20,000

Legislation regarding the Orphan Drug Tax Credit; H.R. 1350, Cameron's Law

Client expense: $180,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.5376 - Inflation Reduction Act of 2022 (117th) H.R.2471 - Consolidated Appropriations Act, 2022 (117th) H.R.485 - Protecting Health Care for All Patients Act of 2023 H.R.1350 - Camerons Law H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022 (117th) S.46 - American Innovation and Manufacturing Act

Client expense: Not reported · Firm income: $60,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

H.R.1092/S.526 - BENEFIT Act of 2023 H.R. 1350, Camerons Law H.R. 1805 (117th) H.R.2471 - Consolidated Appropriations Act, 2022 (117th)

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, The Rare Disease Clinical Trials Pandemic Disruption Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act.

Client expense: $250,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Section 174 R&D Amortization; International tax issues; Issues related to the Orphan Drug Tax Credit; Issues related to the deduction of research and development expenditures; H.R. 1350, Camerons Law.

Client expense: $1,300,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES

Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; Medicare Part D redesign; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R.1805, The Rare Disease Clinical Trials Pandemic Disruption Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act. H.R.2673, The American Innovation and R&D Competitiveness Act.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; and access to non-controlled medications. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R.1350, Camerons Law. H.R. 8295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act. H.R. 1805, The Rare Disease Clinical Trials Pandemic Disruption Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act. Issues related to Medicare Part D redesign.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, The Rare Disease Clinical Trials Pandemic Disruption Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act.

Client expense: Not reported · Firm income: $20,000